311 related articles for article (PubMed ID: 36077584)
21. Revisiting beta thalassemia intermedia: past, present, and future prospects.
Ben Salah N; Bou-Fakhredin R; Mellouli F; Taher AT
Hematology; 2017 Dec; 22(10):607-616. PubMed ID: 28589785
[TBL] [Abstract][Full Text] [Related]
22. Green tea influence on iron overload in thalassemia intermedia patients: a randomized controlled trial.
Al-Momen H; Hussein HK; Al-Attar Z; Hussein MJ
F1000Res; 2020; 9():1136. PubMed ID: 33024552
[No Abstract] [Full Text] [Related]
23. Endocrinopathies, metabolic disorders, and iron overload in major and intermedia thalassemia: serum ferritin as diagnostic and predictive marker associated with liver and cardiac T2* MRI assessment.
Chirico V; Rigoli L; Lacquaniti A; Salpietro V; Piraino B; Amorini M; Salpietro C; Arrigo T
Eur J Haematol; 2015 May; 94(5):404-12. PubMed ID: 25200112
[TBL] [Abstract][Full Text] [Related]
24. Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major.
Wahidiyat PA; Wijaya E; Soedjatmiko S; Timan IS; Berdoukas V; Yosia M
Blood Cells Mol Dis; 2019 Jul; 77():67-71. PubMed ID: 30978615
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
Galanello R
Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.
DivakarJose RR; Delhikumar CG; Ram Kumar G
Indian J Pediatr; 2021 Apr; 88(4):330-335. PubMed ID: 32661609
[TBL] [Abstract][Full Text] [Related]
27. Beta-Thalassemia Intermedia: A Single Thalassemia Center Experience from Northeastern Iraq.
Amin SS; Jalal SD; Ali KM; Mohammed AI; Rasool LK; Osman TJ
Biomed Res Int; 2020; 2020():2807120. PubMed ID: 32190657
[TBL] [Abstract][Full Text] [Related]
28. Serum angiogenin level in sickle cell disease and beta thalassemia patients.
Matter RM; Abdelmaksoud AA; Shams MA; Bebawy EK
Pediatr Hematol Oncol; 2014 Feb; 31(1):50-6. PubMed ID: 24483841
[TBL] [Abstract][Full Text] [Related]
29. Pulmonary Functions in Children With Thalassemia Major.
Ozyoruk D; Misirlioglu ED
J Pediatr Hematol Oncol; 2015 Nov; 37(8):605-10. PubMed ID: 26422288
[TBL] [Abstract][Full Text] [Related]
30. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
31. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN; El Rassi F; Taher AT
Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
[TBL] [Abstract][Full Text] [Related]
32. Iron overload in thalassemia: different organs at different rates.
Taher AT; Saliba AN
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265
[TBL] [Abstract][Full Text] [Related]
33. Modern management of iron overload in thalassemia major patients guided by MRI techniques: real-world data from a long-term cohort study.
Bayraktaroglu S; Karadas N; Onen S; Karapinar DY; Aydinok Y
Ann Hematol; 2022 Mar; 101(3):521-529. PubMed ID: 34985558
[TBL] [Abstract][Full Text] [Related]
34. Serum Hepcidin as a Diagnostic Marker of Severe Iron Overload in Beta-thalassemia Major.
Kaddah AM; Abdel-Salam A; Farhan MS; Ragab R
Indian J Pediatr; 2017 Oct; 84(10):745-750. PubMed ID: 28600663
[TBL] [Abstract][Full Text] [Related]
35. Rapid iron loading in a pregnant woman with transfusion-dependent thalassemia after brief cessation of iron chelation therapy.
Farmaki K; Gotsis E; Tzoumari I; Berdoukas V
Eur J Haematol; 2008 Aug; 81(2):157-9. PubMed ID: 18462251
[TBL] [Abstract][Full Text] [Related]
36. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
Elalfy MS; Saber MM; Adly AA; Ismail EA; Tarif M; Ibrahim F; Elalfy OM
Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
[TBL] [Abstract][Full Text] [Related]
37. The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major.
Di Maggio R; Maggio A
Br J Haematol; 2017 Sep; 178(5):676-688. PubMed ID: 28439891
[TBL] [Abstract][Full Text] [Related]
38. β- and α-Thalassemia intermedia in Basra, Southern Iraq.
Abdulwahid DA; Hassan MK
Hemoglobin; 2013; 37(6):553-63. PubMed ID: 23944608
[TBL] [Abstract][Full Text] [Related]
39. Final Height and Endocrine Complications in Patients with β-Thalassemia Intermedia: Our Experience in Non-Transfused Versus Infrequently Transfused Patients and Correlations with Liver Iron Content.
Yassin MA; Soliman AT; De Sanctis V; Yassin KS; Abdulla MA
Mediterr J Hematol Infect Dis; 2019; 11(1):e2019026. PubMed ID: 31205630
[TBL] [Abstract][Full Text] [Related]
40. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study.
Roghi A; Cappellini MD; Wood JC; Musallam KM; Patrizia P; Fasulo MR; Cesaretti C; Taher AT
Ann Hematol; 2010 Jun; 89(6):585-9. PubMed ID: 20016898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
